Unknown

Dataset Information

0

A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus.


ABSTRACT: GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P329) within the editing domain of LeuRS.

SUBMITTER: Gupta A 

PROVIDER: S-EPMC4862542 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus.

Gupta Arya A   Monteferrante Carmine C   Rasina Dace D   Leitis Gundars G   Randall Christopher P CP   Tomlinson Jennifer H JH   Jirgensons Aigars A   Goessens Wil H F WH   Hays John P JP   O'Neill Alex J AJ  

Antimicrobial agents and chemotherapy 20160422 5


GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P329) within the editing domain of LeuRS. ...[more]

Similar Datasets

2012-08-03 | GSE39868 | GEO
2012-08-03 | E-GEOD-39868 | biostudies-arrayexpress
| S-EPMC3457403 | biostudies-literature
| S-EPMC6702299 | biostudies-literature
| S-EPMC4954867 | biostudies-literature
| S-EPMC4125540 | biostudies-literature
| S-EPMC6783909 | biostudies-literature
| S-EPMC5740382 | biostudies-literature
| S-EPMC6470132 | biostudies-literature
| S-EPMC3552489 | biostudies-literature